EXHIBIT 10.18
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks
denote omissions.
LICENSE AGREEMENT
Entered into by and between AstraZeneca AB and The Medicines Company as of the 18th day of December,
2003
TABLE OF CONTENTS
-i-
1
LICENSE AGREEMENT
This Agreement is entered into as of the 18th day of December, 2003 (the "Effective Date")
by and between
ASTRAZENECA AB, a company incorporated under the laws of Sweden with its registered office at SE-151
85 Sodertalje, Sweden ("ASTRAZENECA") and
1. DEFINITIONS...........................................................2
2. GRANT OF LICENSE.....................................................11
3. DEVELOPMENT AND COMMERCIALIZATION....................................15
4. SUPPLY MATTERS.......................................................25
5. EXCHANGE OF INFORMATION..............................................27
6. CONSIDERATION........................................................29
7. INTELLECTUAL PROPERTY - PROSECUTION AND MAINTENANCE..................39
8. CLAIMS REGARDING INFRINGEMENT AND INVALIDITY.........................42
9. TRADEMARK............................................................46
10. INDEMNITY............................................................47
11. CONFIDENTIALITY......................................................49
12. ADVERSE EVENTS.......................................................51
13. REPRESENTATIONS, WARRANTIES AND COVENANTS............................52
14. TERM AND TERMINATION.................................................55
15. CONSEQUENCES OF TERMINATION..........................................57
16. FORCE MAJEURE........................................................60
17. GENERAL PROVISIONS...................................................61
18. GOVERNING LAW AND ARBITRATION..................